5P Strategies for Management of Multiple Endocrine Neoplasia Type 2: A Paradigm of Precision Medicine

Shu-Yuan Li1, Yi-Qiang Ding2, You-Liang Si2

  • 1International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.

Insights

Multiple endocrine neoplasia type 2 (MEN2) management can be improved with "5P" strategies: prevention, prediction, personalization, psychological support, and participation. These approaches, guided by RET proto-oncogene mutations, enhance patient outcomes and survival for this neuroendocrine cancer syndrome.

Area of Science:

  • Endocrinology
  • Oncology
  • Genetics

Background:

  • Multiple endocrine neoplasia type 2 (MEN2) is a hereditary neuroendocrine cancer syndrome.
  • MEN2 is primarily caused by germline mutations in the RET proto-oncogene.
  • MEN2 presents in two main forms: MEN2A and MEN2B, often involving medullary thyroid carcinoma, pheochromocytoma, and hyperparathyroidism.

Purpose of the Study:

  • To propose a comprehensive
  • 5P
  • management framework for MEN2.
  • To highlight the role of RET proto-oncogene mutations in MEN2 management.
  • To emphasize the integration of precision medicine strategies for improved patient outcomes.

Main Methods:

  • Review of existing literature and clinical guidelines for MEN2 management.
  • Focus on RET proto-oncogene mutation analysis for diagnosis and risk stratification.
  • Integration of diagnostic markers (calcitonin, metanephrine/normetanephrine, parathyroid hormone) for prediction.
  • Incorporation of genetic testing (prenatal diagnosis, preimplantation genetic testing) for prevention.

Main Results:

  • The
  • 5P
  • strategies (prevention, prediction, personalization, psychological support, participation) offer a structured approach to MEN2 management.
  • RET mutation testing enables early diagnosis, risk stratification, and personalized treatment.
  • Multidisciplinary participation and psychological support are crucial for comprehensive care.

Conclusions:

  • The proposed
  • 5P
  • strategies represent a precision medicine model for MEN2.
  • Effective implementation can significantly improve disease-free survival and overall survival.
  • These strategies aim to prevent adverse outcomes, including mortality and major morbidity, associated with MEN2.

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.3K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K